Ali Moiin is a Dermatology physician affiliated with Wayne State University. OpenAlex indexes 42 publications with 333 citations (h-index 10); ClinicalTrials.gov lists 2 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
1575 W Big Beaver Rd
Suite C12
Troy, MI 480843525
Telephone
248-643-7677Registry record last updated 6 Oct 2014.
Clinical trials
- Phase 1 Trial of ST-001 nanoFenretinide in Relapsed/ Refractory Small Cell Lung Cancer
Sponsor: SciTech Development, Inc.
- Phase 1 Trial of ST-001 nanoFenretinide in Relapsed/Refractory T-cell Non-Hodgkin Lymphoma
Sponsor: SciTech Development, Inc.
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
24 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- GENZYME CORPORATIONProgram year202512 payments
- Cipher Pharmaceuticals US LLCProgram year20251 payment
- Galderma Laboratories, L.P.Program year202512 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Safety and efficacy of barzolvolimab, an anti–KIT monoclonal antibody, in adults with moderate-to-severe prurigo nodularis: A randomized phase 1b intravenous single dose study
Journal of the American Academy of Dermatology
2025 - Lebrikizumab Improves Atopic Dermatitis in Adult and Adolescent Patients With Skin of Color: 16-Week Results From the ADmirable Study
SKIN The Journal of Cutaneous Medicine
2025 - Le lébrikizumab améliore les démangeaisons/douleurs cutanées et l’interférence des démangeaisons sur le sommeil chez les patients adultes/adolescents atteints de dermatite atopique modérée à sévère avec peau foncée à la semaine 16 (étude ADmirable)
Annales de Dermatologie et de Vénéréologie - FMC
2025
Similar KOLs
Other experts from the same institution or the same specialty.
Pranatharthi Chandrasekar, MD
Wayne State University
Bret Hughes, MD
Wayne State University
Mark Juzych, MD, MHSA
Wayne State University
Lubina Arjyal, MD
Wayne State University
Robert Modlin, MD
University of California, Los Angeles
Heidi Kong, MD
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Jon Hanifin, MD
Oregon Health & Science University (OHSU)
Victoria Werth, MD
Perelman School of Medicine at the University of Pennsylvania
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”